Akero Therapeutics (AKRO) News Today $44.45 -0.63 (-1.40%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Simplify Asset Management Inc. Has $7.36 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)Simplify Asset Management Inc. lowered its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 6.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 264,677 shares of the company's stock after selling 19,089 shares during the peMarch 24 at 6:18 AM | marketbeat.comContrasting Akero Therapeutics (NASDAQ:AKRO) & Rezolute (NASDAQ:RZLT)March 24 at 1:24 AM | americanbankingnews.comIntech Investment Management LLC Buys 20,795 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)Intech Investment Management LLC raised its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 121.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 37,902 shares of the company'March 23 at 4:11 AM | marketbeat.comYiheng Capital Management L.P. Has $18.53 Million Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Yiheng Capital Management L.P. reduced its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 12.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 666,145 shares of the company's stock afteMarch 22 at 6:14 AM | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Stock Position Raised by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. lifted its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 1.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 540,692 shMarch 21, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 10,000 SharesAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 10,000 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $44.76, for a total transaction of $447,600.00. Following the sale, the insider now owns 95,034 shares of the company's stock, valued at $4,253,721.84. This trade represents a 9.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.March 19, 2025 | marketbeat.comKennondale Capital Management LLC Makes New $785,000 Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO)Kennondale Capital Management LLC bought a new position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 28,217 shares of thMarch 19, 2025 | marketbeat.comCatriona Yale Sells 10,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockMarch 19, 2025 | insidertrades.comBank of New York Mellon Corp Cuts Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Bank of New York Mellon Corp lessened its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 3.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 200,430 shares of the company's stock after selling 6,414 sharesMarch 17, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Shares Acquired by AlphaQuest LLCAlphaQuest LLC increased its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 32,588.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,172 shares of the company's stock after purchaMarch 16, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Given Consensus Rating of "Buy" by AnalystsMarch 16, 2025 | americanbankingnews.comAkero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 607 SharesAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 607 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total value of $27,242.16. Following the transaction, the chief operating officer now owns 200,540 shares in the company, valued at approximately $9,000,235.20. This trade represents a 0.30 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.March 15, 2025 | marketbeat.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 614 Shares of StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 614 shares of the firm's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total transaction of $27,556.32. Following the sale, the insider now owns 95,034 shares in the company, valued at $4,265,125.92. The trade was a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.March 15, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) CFO Sells $30,338.88 in StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CFO William Richard White sold 676 shares of Akero Therapeutics stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total value of $30,338.88. Following the completion of the transaction, the chief financial officer now owns 61,959 shares of the company's stock, valued at approximately $2,780,719.92. The trade was a 1.08 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.March 15, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 1,738 SharesAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CEO Andrew Cheng sold 1,738 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total value of $78,001.44. Following the completion of the sale, the chief executive officer now owns 654,324 shares of the company's stock, valued at approximately $29,366,061.12. This trade represents a 0.26 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.March 15, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 607 SharesMarch 15, 2025 | insidertrades.comGreat Lakes Advisors LLC Purchases Shares of 193,384 Akero Therapeutics, Inc. (NASDAQ:AKRO)Great Lakes Advisors LLC acquired a new position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 193,384 shares of the company's stock, valueMarch 14, 2025 | marketbeat.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Sells 30,000 Shares of StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CEO Andrew Cheng sold 30,000 shares of Akero Therapeutics stock in a transaction on Monday, March 10th. The stock was sold at an average price of $41.77, for a total value of $1,253,100.00. Following the completion of the sale, the chief executive officer now directly owns 656,062 shares of the company's stock, valued at approximately $27,403,709.74. The trade was a 4.37 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.March 13, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Stock Price Up 5.5% - Here's What HappenedAkero Therapeutics (NASDAQ:AKRO) Stock Price Up 5.5% - Here's WhyMarch 13, 2025 | marketbeat.comAndrew Cheng Sells 30,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockMarch 13, 2025 | insidertrades.comProficio Capital Partners LLC Acquires Shares of 11,490 Akero Therapeutics, Inc. (NASDAQ:AKRO)Proficio Capital Partners LLC bought a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 11,490 shares of the company'sMarch 12, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Rating of "Buy" from AnalystsAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) has received a consensus rating of "Buy" from the nine research firms that are presently covering the stock, MarketBeat reports. Nine research analysts have rated the stock with a buy recommendation. The average 1 year price target among broMarch 11, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $556,625.00 in StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 12,500 shares of Akero Therapeutics stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $44.53, for a total value of $556,625.00. Following the completion of the sale, the insider now directly owns 170,237 shares in the company, valued at $7,580,653.61. This represents a 6.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.March 8, 2025 | marketbeat.comEvercore ISI Reaffirms Their Buy Rating on Akero Therapeutics (AKRO)March 7, 2025 | markets.businessinsider.comHC Wainwright Issues Optimistic Outlook for AKRO EarningsAkero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) - Analysts at HC Wainwright raised their Q1 2025 earnings estimates for Akero Therapeutics in a research report issued to clients and investors on Monday, March 3rd. HC Wainwright analyst E. Arce now expects that the company will post earningsMarch 7, 2025 | marketbeat.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 1,000 Shares of StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) VP Patrick Lamy sold 1,000 shares of Akero Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $48.09, for a total value of $48,090.00. Following the completion of the transaction, the vice president now owns 33,492 shares in the company, valued at approximately $1,610,630.28. This represents a 2.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.March 6, 2025 | marketbeat.comJonathan Young Sells 50,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 50,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $44.86, for a total value of $2,243,000.00. Following the transaction, the chief operating officer now owns 201,147 shares in the company, valued at $9,023,454.42. This represents a 19.91 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.March 6, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy Sells 1,000 SharesMarch 6, 2025 | insidertrades.comY Intercept Hong Kong Ltd Has $249,000 Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)Y Intercept Hong Kong Ltd lowered its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 47.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 8,950 shares of the company's stock after selling 7,966 shares during the period. Y InteMarch 5, 2025 | marketbeat.comShort Interest in Akero Therapeutics, Inc. (NASDAQ:AKRO) Increases By 32.0%Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) saw a large growth in short interest in February. As of February 15th, there was short interest totalling 4,790,000 shares, a growth of 32.0% from the January 31st total of 3,630,000 shares. Based on an average daily trading volume, of 1,170,000 shares, the short-interest ratio is presently 4.1 days.March 4, 2025 | marketbeat.comAkero Therapeutics price target raised to $75 from $72 at H.C. WainwrightMarch 3, 2025 | markets.businessinsider.comJ.P. Morgan Sticks to Its Buy Rating for Akero Therapeutics (AKRO)March 3, 2025 | markets.businessinsider.comAkero Therapeutics (NASDAQ:AKRO) Given New $75.00 Price Target at HC WainwrightHC Wainwright boosted their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Monday.March 3, 2025 | marketbeat.comAkero Therapeutics price target lowered to $90 from $96 at Morgan StanleyMarch 2, 2025 | markets.businessinsider.comBank of America Securities Remains a Buy on Akero Therapeutics (AKRO)March 2, 2025 | markets.businessinsider.comAkero Therapeutics (NASDAQ:AKRO) Releases Earnings Results, Misses Expectations By $0.01 EPSAkero Therapeutics (NASDAQ:AKRO - Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01).March 1, 2025 | marketbeat.comAkero Therapeutics reports Q4 EPS (99c), consensus ($1.12)February 28, 2025 | markets.businessinsider.com3 Mid-Caps Worth Watching Closely in March (AKRO)Unlike their mega-cap counterparts, which tend to grind, mid-caps can soar or crash within days, driven by headlines and pure speculation.February 28, 2025 | marketbeat.comAkero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateFebruary 28, 2025 | globenewswire.comIs Akero Therapeutics Inc. (AKRO) the Best Performing Mid Cap Stock to Buy According to Analysts?February 27, 2025 | msn.comAkero Therapeutics (AKRO) Projected to Post Quarterly Earnings on ThursdayAkero Therapeutics (NASDAQ:AKRO) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports.February 27, 2025 | marketbeat.comPhillip Securities Reaffirms Their Buy Rating on Akero Therapeutics (AKRO)February 24, 2025 | markets.businessinsider.comAkero Therapeutics, Inc. (AKRO): the Best Performing Pharma Stock So Far in 2025February 23, 2025 | insidermonkey.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 10,000 Shares of StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 10,000 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $49.87, for a total value of $498,700.00. Following the transaction, the insider now directly owns 95,648 shares in the company, valued at approximately $4,769,965.76. This represents a 9.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.February 22, 2025 | marketbeat.comThe Healthcare Sector and its Dynamics in the Stock MarketFebruary 19, 2025 | uk.finance.yahoo.comAkero Therapeutics, Inc. (AKRO): the Best Performing Healthcare Stock So Far in 2025February 19, 2025 | msn.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Up 8.4% in JanuaryAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) saw a significant growth in short interest in January. As of January 31st, there was short interest totalling 3,630,000 shares, a growth of 8.4% from the January 15th total of 3,350,000 shares. Based on an average trading volume of 1,150,000 shares, the short-interest ratio is currently 3.2 days.February 17, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Recommendation of "Buy" by BrokeragesAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) has been assigned an average recommendation of "Buy" from the nine ratings firms that are currently covering the firm, Marketbeat reports. Nine investment analysts have rated the stock with a buy recommendation. The average 1-year price targFebruary 14, 2025 | marketbeat.comabrdn plc Grows Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)abrdn plc grew its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 118.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 269,782 shares of the company's stock after purchasing an additional 146,424 shares duFebruary 9, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $1,059,562.50 in StockFebruary 8, 2025 | insidertrades.com Remove Ads Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address AKRO Media Mentions By Week AKRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKRO News Sentiment▼0.890.63▲Average Medical News Sentiment AKRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKRO Articles This Week▼98▲AKRO Articles Average Week Remove Ads Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intra-Cellular Therapies News Moderna News Genmab A/S News Dr. Reddy's Laboratories News Viatris News Ascendis Pharma A/S News Vaxcyte News Qiagen News Roivant Sciences News Sarepta Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKRO) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKRO Stock Free AKRO Stock Alerts